Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.



  • Immunotherapy with pembrolizumab is more efficient than treatment with ipilimumab in patients with advanced melanoma

    In a large international study, in which the Netherlands Cancer Institute was the only Dutch participating center, the drug pembrolizumab clearly outperformed treatment with ipilimumab in patients with advanced melanoma. Patients who received pembrolizumab showed better progression-free survival and suffered fewer side effects. The results were published in the New England Journal of Medicine on April 19th.

    Read More
  • On Thursday, April 23th Ingar Seemann will defend her thesis

    The thesis is entitled 'Radiation and anthracycline induced cardiovascular damage. Late side effects of thoracic cancer treatment'. The public defense will take place at 13:34h at the aula of the Free University, De Boelelaan 1105, Amsterdam.

    Read More
  • More news

Comprehensive Cancer Centre

'The Netherlands Cancer Institute, a center of excellence for the benefit of cancer patients.'

Support Us